Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Oxytocin (OT) is a small, naturally occurring peptide currently in clinical use to stimulate lactation in breastfeeding women. The intranasal administration of OT has recently attracted attention as a potential novel treatment in several psychiatric disorders including autism. However, given the anatomy of the nasal cavity, the current design of nasal sprays would be expected to provide an inadequate delivery of medication to the areas of the nasal cavity where direct transport into the brain via the olfactory nerve could potentially occur. OptiNose has developed an intranasal delivery device that provides improved reproducibility of nasal delivery, improved deposition to the upper posterior regions of the nasal cavity where the olfactory nerve innervates the nasal cavity.

The primary objective of this study is to identify any differences between single dose 8 or 24 international units (IU) oxytocin delivered intranasally with the optimised OptiNose device and 1 IU oxytocin administered as slow intravenous infusion in healthy volunteers. This will be measured in terms of brain activity as measured with functional magnetic resonance imaging (fMRI), performance on cognitive tests, and physiological markers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inhaled Oxytocin and HPA Axis Reactivity

NCT03593473

Depression, Postpartum Anxiety Disorders Stress, Psychological

COMPLETED PHASE2

Oxytocin and Pain Sensitivity and Threshold

NCT01988649

Pain

WITHDRAWN NA

Intranasal Oxytocin and Maternal Neglect

NCT02737436

Maternal Behavior

COMPLETED NA

Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years

NCT03114371

Prader-Willi Syndrome

COMPLETED NA

Effect of Oral Oxytocin on Women's Response to Emotional Stimuli

NCT05073939

Healthy

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Male Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 international unit (IU) intravenous oxytocin

Using a double-dummy design participants will be administered 1 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) slow infusion with varying infusion rate over 20 minutes and placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device. Subject to pilot data this may be increased to 2 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) and the infusion time/rate may change to best match the pharmacokinetic profile of intranasally administered oxytocin.

Group Type ACTIVE_COMPARATOR

1 IU intravenous oxytocin

Intervention Type DRUG

Placebo

Using a double-dummy design participants will be administered Placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device and placebo delivered intravenously (0.9% sodium chloride 200 ml slow infusion for 20 minutes)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

8IU intranasal oxytocin

Using a double-dummy design participants will be administered 8IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)

Group Type EXPERIMENTAL

8IU intranasal oxytocin

Intervention Type DRUG

24IU intranasal oxytocin

Using a double-dummy design participants will be administered 24IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)

Group Type EXPERIMENTAL

24 IU intranasal oxytocin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

8IU intranasal oxytocin

Intervention Type DRUG

24 IU intranasal oxytocin

Intervention Type DRUG

1 IU intravenous oxytocin

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, male subjects aged 18 to 35 years inclusive.
* Subjects must be in good general health, as determined by the investigator.
* Subject's pre-study physical examination, vital signs and electrocardiogram (ECG) are normal or do not show any clinically significant abnormalities as determined by the investigator. Vital signs must not have any clinically significant deviations outside of the following ranges when measured sitting after 5 minutes rest:

1. Heart rate: 40 to 90 beats per minute
2. Systolic blood pressure (BP): 90 to 140 mmHg
3. Diastolic BP: 50 to 90 mmHg
4. Oral temperature: 36.0 to 37.5°C
5. Respiratory rate: 12 - 18 breaths per minute
* Body Mass Index (BMI) of 18.5 - 29.9 kg/m2 (both inclusive)
* Subjects must be able to communicate well with the Investigator, to understand and comply with the requirements of the study, and understand and sign the written informed consent
* Provision of written informed consent.

Exclusion Criteria

An ear, nose and throat (ENT) specialist will inspect the noses of all individuals who enter the study.

* Individuals showing major septal deviation or a significantly altered nasal epithelium.
* Participants with evidence of previous nasal disease, surgery, and dependence on inhaled drugs.
* Individuals with current significant nasal congestion due to common colds.
* Subjects with a clinically relevant history of significant hepatic, renal, endocrine, cardiac, nervous, psychiatric, gastrointestinal, pulmonary, haematological or metabolic disorder.
* Subjects with current or history of, any clinically significant disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
* Subject is taking any regular prescribed or over-the-counter (OTC) medications including vitamin supplements and herbal remedies. There must be at least 14 days between stopping these products and the first dose of study medication).
* Systemic illness requiring treatment within 2 weeks prior to Study Day 1.
* History of significant drug or alcohol abuse (as per a self-report measure / instrument; World Health Organisation criteria/Alcohol use disorders identification test/Drug use disorders identification test). Subjects with a positive screen for alcohol or drugs of abuse at screening/admission will be excluded from participation in the study.
* Self-reported significant psychiatric conditions.
* Any abnormal laboratory values outside normal range, and which is clinically significant as deemed by investigator.
* Full scale intelligence quotient (IQ) \< 75 (due to the prerequisite ability to complete self report measures).
* Known allergic reactions or hypersensitivity to any component of the study medication in the nasal spray, such as E216, E218 and chlorobutanol hemihydrate.
* Participation in any (other) clinical trial with an investigational medicinal product or medical device within 3 months prior to randomisation.
* Current evidence of any mental or physical disorder or collaboration attitude which, in the judgment of the investigator makes the subject unsuitable for enrolment, and/or may interfere with the study evaluations or affect subject's safety.
* Subjects with any metal implants.
* Subjects with claustrophobia.
* Other unspecified reasons that, in the opinion of the Investigator or the sponsor make the subject unsuitable for enrolment.
* Subjects with female partners of child-bearing potential must use an adequate form of contraception prior to entry into the study until three months following the post-study medical visit. Subjects must not have a partner who is either pregnant or breastfeeding for the duration of the study. Adequate contraception is defined as the usage by the female partner of any form of hormonal contraception or intra-uterine device (which should be established prior to the start of the study) plus usage by one of the partners of an additional spermicide- containing barrier method of contraception.

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes